Through the program, the company will introduce seven new manufacturing sites that will be completed and operational by the end of 2020.
Saint-Gobain Life Sciences announced the launch of its EUR 70-million (US$77-million) global expansion program on Nov. 21, 2019. Through the program, the company will introduce seven new manufacturing sites that will be completed and operational by the end of 2020.
According to a company press release, the program was kicked off with the construction of the company’s Bangalore, India, site in September of 2019, and, recently, the company ended construction on its Largo, FL, facility for the production of its C-Flex tubing, molded connections, and assemblies. The additional facilities will be located in Beaverton, MI; Charny, France; Dublin, Ireland; Hangzhou, China; and Songdo, South Korea.
“This is an exciting time in our business,” said Jean Angus, CEO, Saint-Gobain Life Sciences, in the press release. “This is the execution of a multi-year plan to expand our global manufacturing footprint, which will enhance our ability to service our Life Sciences customers globally with redundant manufacturing facilities. We are increasing the regional availability of our products and our ability to meet customers’ growing demands.”
Source: Saint-Gobain Life Sciences
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.